Journal article
Systemic therapy for melanoma: ASCO guideline
R Seth, H Messersmith, V Kaur, JM Kirkwood, R Kudchadkar, JL McQuade, A Provenzano, U Swami, J Weber, KC Alluri, S Agarwala, PA Ascierto, MB Atkins, N Davis, MS Ernstoff, MB Faries, JS Gold, S Guild, DE Gyorki, NI Khushalani Show all
Journal of Clinical Oncology | LIPPINCOTT WILLIAMS & WILKINS | Published : 2020
DOI: 10.1200/JCO.20.00198
Abstract
PURPOSE To provide guidance to clinicians regarding the use of systemic therapy for melanoma. METHODS ASCO convened an Expert Panel and conducted a systematic review of the literature. RESULTS A systematic review, one meta-analysis, and 34 additional randomized trials were identified. The published studies included a wide range of systemic therapies in cutaneous and noncutaneous melanoma. RECOMMENDATIONS In the adjuvant setting, nivolumab or pembrolizumab should be offered to patients with resected stage IIIA/B/C/D BRAF wild-type cutaneous melanoma, while either of those two agents or the combination of dabrafenib and trametinib should be offered in BRAF-mutant disease. No recommendation cou..
View full abstract